This site is intended for U.S. health care professionals only.

LENVIMA® (lenvatinib) capsules 10 mg and 4 mg logo
Select an Indication
RAI-refractory DTC 1st-Line treatment of aRCC 2nd-Line treatment of aRCC 1st-Line treatment of uHCC Advanced EC
LENVIMA® for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer

SELECT: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial in patients with locally recurrent or metastatic RAI-R DTC1

Study design for SELECT for LENVIMA in radioactive iodine-refractory differentiated thyroid cancer Study design for SELECT for LENVIMA in radioactive iodine-refractory differentiated thyroid cancer mobile

SELECT=Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid; RAI-R=radioactive iodine-refractory; DTC=differentiated thyroid cancer; VEGF=vascular endothelial growth factor; VEGFR=vascular endothelial growth factor receptor; PFS=progression-free survival; ORR=objective response rate; OS=overall survival.

aDetermined by blinded, independent radiologic review using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Baseline patient characteristics2,3

Baseline patient characteristics in the SELECT trial for RAI-R differentiated thyroid cancer Baseline patient characteristics in the SELECT trial for RAI-R differentiated thyroid cancer mobile

  • 4 out of 10 patients were >65 years old

The median cumulative RAI activity administered prior to study entry was 350 mCi (12.95 GBq).1

ECOG=Eastern Cooperative Oncology Group; RAl=radioactive iodine; mCi=millicurie; GBq=gigabecquerel.

aHistologic findings were determined from investigators’ reports.

See efficacy data in the SELECT trial
RAI-R DTC Home Efficacy Results